Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sarcoidosis Lung Clear all
Completed Phase 2Phase 3 Interventional Results available

Tadalafil for Sarcoidosis Associated Pulmonary Hypertension

NCT01324999
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Tadalafil
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 26, 2026, 9:34 AM EDT
Terminated Phase 1 Interventional

Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

NCT01440192
View directory record Official record
Conditions
Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
Interventions
PDA001 (cenplacel-L)
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 26, 2026, 9:34 AM EDT
Not listed Phase 4 Interventional

Riociguat for Sarcoidosis Associated Pulmonary Hypertension

NCT02625558
View directory record Official record
Conditions
Sarcoidosis
Interventions
Riociguat, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

NCT05415137
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

NCT03824392
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 26, 2026, 9:34 AM EDT
Not listed Phase 4 Interventional

Pirfenidone for Progressive Fibrotic Sarcoidosis

NCT03260556
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Pirfenidone, Placebos
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 26, 2026, 9:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039
View directory record Official record
Conditions
Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 26, 2026, 9:34 AM EDT
Recruiting No phase listed Observational

Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens

NCT05171478
View directory record Official record
Conditions
Lung Cancer, Sarcoidosis
Interventions
Full-field optical coherence tomography
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 26, 2026, 9:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT05890729
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
XTMAB-16 or Placebo
Drug
Lead sponsor
Xentria, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 9:34 AM EDT
Recruiting No phase listed Observational

Interstitial Lung Disease Research Unit Biobank

NCT05392881
View directory record Official record
Conditions
Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Hypersensitivity Pneumonitis
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 26, 2026, 9:34 AM EDT
Terminated No phase listed Observational

Stromal Gene Expression During Pulmonary Sarcoidosis

NCT00837668
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 26, 2026, 9:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

NCT02888080
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Albany, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study

NCT02265874
View directory record Official record
Conditions
Sarcoidosis
Interventions
Habitrol, Placebo to Habitrol
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 26, 2026, 9:34 AM EDT
Recruiting No phase listed Observational

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

NCT05567133
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
200 participants
Timeline
2023 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 26, 2026, 9:34 AM EDT
Completed No phase listed Observational

Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis

NCT00560989
View directory record Official record
Conditions
Sarcoidosis, Berylliosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

Rituximab for Pulmonary Sarcoidosis

NCT00855205
View directory record Official record
Conditions
Sarcoidosis
Interventions
Rituximab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 26, 2026, 9:34 AM EDT
Terminated Phase 3 Interventional

Mycophenolate for Pulmonary Sarcoidosis

NCT00262132
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Mycophenolate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 2Phase 3 Interventional

Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

NCT00581607
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Bosentan, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
New York, New York • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 26, 2026, 9:34 AM EDT
Terminated Phase 1 Interventional

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

NCT01445392
View directory record Official record
Conditions
Mesothelioma
Interventions
Multicycle SS1P, Pemetrexed, Cisplatin, Single cycle SS1P
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 26, 2026, 9:34 AM EDT
Not listed No phase listed Observational

Patient-Reported Outcome Study of Project ECHO for ILD

NCT05450276
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 26, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin to Treat Pulmonary Sarcoidosis

NCT00279708
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Atorvastatin, Placebo Oral Tablet
Drug · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 26, 2026, 9:34 AM EDT